An Australian vote for pharma: generics
This article was originally published in Scrip
Executive Summary
Leading brands that are set to lose patent protection in 2010-12 collectively generated $1.08 billion in sales in Australia in 2009. Products facing generic competition in Australia over this period include Wyeth (Pfizer's) Enbrel (etanercept), Pfizer's Lipitor (atorvastatin) and Lilly's Zyprexa (olanzapine). In 2012, $984 million worth of products will go off-patent, most prominently Lipitor.